These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22005235)

  • 1. N-acetylcysteine and acute renal failure: are we doing too little too late?
    Rachoin JS
    Crit Care Med; 2011 Nov; 39(11):2574-5. PubMed ID: 22005235
    [No Abstract]   [Full Text] [Related]  

  • 2. N-acetylcysteine versus Dopamine to Prevent Acute Kidney Injury after Cardiac Surgery in Patients with Preexisting Moderate Renal Insufficiency.
    Savluk OF; Guzelmeric F; Yavuz Y; Cevirme D; Gurcu E; Ogus H; Orki T; Kocak T
    Braz J Cardiovasc Surg; 2017; 32(1):8-14. PubMed ID: 28423123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Q: Should N-acetylcysteine be used routinely to prevent contrast-induced acute kidney injury?
    Sivalingam SK; Hariharan MV; Braden GL; Freda BJ
    Cleve Clin J Med; 2012 Nov; 79(11):746-9. PubMed ID: 23125323
    [No Abstract]   [Full Text] [Related]  

  • 4. Protective effect of N-acetylcysteine (NAC) on renal ischemia/reperfusion injury through Nrf2 signaling pathway.
    Zhang L; Zhu Z; Liu J; Zhu Z; Hu Z
    J Recept Signal Transduct Res; 2014 Oct; 34(5):396-400. PubMed ID: 24734887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcysteine for the prevention of renal outcomes in patients with diabetes mellitus undergoing coronary and peripheral vascular angiography: a substudy of the acetylcysteine for contrast-induced nephropathy trial.
    Berwanger O; Cavalcanti AB; Sousa AM; Buehler A; Castello-Júnior HJ; Cantarelli MJ; Mangione JA; Bergo RR; São Thiago LE; Nunes PM; da Motta PA; Kodama A; Victor E; Carvalho VO; Sousa JE;
    Circ Cardiovasc Interv; 2013 Apr; 6(2):139-45. PubMed ID: 23572490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
    Briguori C; Visconti G; Focaccio A; Airoldi F; Valgimigli M; Sangiorgi GM; Golia B; Ricciardelli B; Condorelli G;
    Circulation; 2011 Sep; 124(11):1260-9. PubMed ID: 21844075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimizing the renal toxicity of iodinated contrast.
    McCullough PA; Khambatta S; Jazrawi A
    Circulation; 2011 Sep; 124(11):1210-1. PubMed ID: 21911794
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-blinded, randomized controlled trial of N-acetylcysteine for prevention of acute kidney injury in high risk patients undergoing off-pump coronary artery bypass.
    Song JW; Shim JK; Soh S; Jang J; Kwak YL
    Nephrology (Carlton); 2015 Feb; 20(2):96-102. PubMed ID: 25384603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of acute renal failure with N-acetylcysteine--enough is enough?
    Koller H; Rosenkranz AR
    Kidney Int; 2004 Sep; 66(3):1292-3; author reply 1292-3. PubMed ID: 15327439
    [No Abstract]   [Full Text] [Related]  

  • 11. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
    J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ataei S; Hadjibabaie M; Moslehi A; Taghizadeh-Ghehi M; Ashouri A; Amini E; Gholami K; Hayatshahi A; Vaezi M; Ghavamzadeh A
    Hematol Oncol; 2015 Jun; 33(2):67-74. PubMed ID: 24711000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal protection by N-acetylcysteine.
    Shehabi Y
    Br J Anaesth; 2007 Feb; 98(2):270; author reply 270-1. PubMed ID: 17251216
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography.
    Tadros GM; Mouhayar EN; Akinwande AO; Campbell B; Wood C; Blankenship JA
    J Invasive Cardiol; 2003 Jun; 15(6):311-4. PubMed ID: 12777667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure.
    Morgan PG; Georghiou M; Flynn F; Jaggar S
    Br J Anaesth; 2007 Jul; 99(1):143; author reply 143-4. PubMed ID: 17573400
    [No Abstract]   [Full Text] [Related]  

  • 16. Beneficial effects of N-acetylcysteine and ebselen on renal ischemia/reperfusion injury.
    Kizilgun M; Poyrazoglu Y; Oztas Y; Yaman H; Cakir E; Cayci T; Akgul OE; Kurt YG; Yaren H; Kunak ZI; Macit E; Ozkan E; Taslipinar MY; Turker T; Ozcan A
    Ren Fail; 2011; 33(5):512-7. PubMed ID: 21545313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury.
    Seifi B; Kadkhodaee M; Delavari F; Mikaeili S; Shams S; Ostad SN
    Ren Fail; 2012; 34(5):610-5. PubMed ID: 22364443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose of N-acetylcystein prevents acute kidney injury in chronic kidney disease patients undergoing myocardial revascularization.
    Santana-Santos E; Gowdak LH; Gaiotto FA; Puig LB; Hajjar LA; Zeferino SP; Drager LF; Shimizu MH; Bortolotto LA; De Lima JJ
    Ann Thorac Surg; 2014 May; 97(5):1617-23. PubMed ID: 24657033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
    Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
    J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.